CN104321074B - 生长抑素类似物与11β‑羟化酶抑制剂的组合 - Google Patents

生长抑素类似物与11β‑羟化酶抑制剂的组合 Download PDF

Info

Publication number
CN104321074B
CN104321074B CN201380027076.7A CN201380027076A CN104321074B CN 104321074 B CN104321074 B CN 104321074B CN 201380027076 A CN201380027076 A CN 201380027076A CN 104321074 B CN104321074 B CN 104321074B
Authority
CN
China
Prior art keywords
combination
compound
cushing
syndrome
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380027076.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104321074A (zh
Inventor
G·H·格里克
H·A·施密德
鲁托密斯基 M·R·马尔多纳多
L·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104321074A publication Critical patent/CN104321074A/zh
Application granted granted Critical
Publication of CN104321074B publication Critical patent/CN104321074B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380027076.7A 2012-04-12 2013-04-10 生长抑素类似物与11β‑羟化酶抑制剂的组合 Active CN104321074B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623117P 2012-04-12 2012-04-12
US61/623,117 2012-04-12
PCT/EP2013/057515 WO2013153129A1 (en) 2012-04-12 2013-04-10 Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

Publications (2)

Publication Number Publication Date
CN104321074A CN104321074A (zh) 2015-01-28
CN104321074B true CN104321074B (zh) 2017-09-08

Family

ID=48289057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380027076.7A Active CN104321074B (zh) 2012-04-12 2013-04-10 生长抑素类似物与11β‑羟化酶抑制剂的组合

Country Status (13)

Country Link
US (1) US9333234B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2836228B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6383352B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102136214B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104321074B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013246908B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014025058B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2869442C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2980806T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN09240A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX362533B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2663455C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013153129A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786443C (en) * 2010-01-14 2018-12-11 Novartis Ag Use of an adrenal hormone-modifying agent
US10143680B2 (en) * 2014-07-07 2018-12-04 Novartis Ag Pharmaceutical dosage forms
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1334742A (zh) * 1998-07-30 2002-02-06 研究及应用科学协会股份有限公司 促生长素抑制素类似物兰瑞肽的应用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081499A2 (en) * 2001-04-09 2002-10-17 The Administrators Of The Tulane Educational Fund Somatostatin agonists
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
JP5575913B2 (ja) * 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
CA2786443C (en) * 2010-01-14 2018-12-11 Novartis Ag Use of an adrenal hormone-modifying agent
WO2013131879A1 (en) * 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1334742A (zh) * 1998-07-30 2002-02-06 研究及应用科学协会股份有限公司 促生长素抑制素类似物兰瑞肽的应用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial;M. Boscaro et al.;《J Clin Endocrinol Metab》;20090131;第94卷(第1期);摘要 *

Also Published As

Publication number Publication date
CA2869442A1 (en) 2013-10-17
EP2836228A1 (en) 2015-02-18
EP2836228B1 (en) 2024-03-20
JP6383352B2 (ja) 2018-08-29
US20150087588A1 (en) 2015-03-26
KR20150004831A (ko) 2015-01-13
RU2663455C2 (ru) 2018-08-06
MX2014012321A (es) 2015-09-24
BR112014025058A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-20
BR112014025058B1 (pt) 2022-07-12
RU2014145351A (ru) 2016-06-10
KR102136214B1 (ko) 2020-07-22
AU2013246908B2 (en) 2016-06-30
MX362533B (es) 2019-01-23
CA2869442C (en) 2020-09-08
US9333234B2 (en) 2016-05-10
CN104321074A (zh) 2015-01-28
AU2013246908A1 (en) 2014-10-23
JP2015512923A (ja) 2015-04-30
ES2980806T3 (es) 2024-10-03
IN2014DN09240A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-10
WO2013153129A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
TWI621624B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
CN104321074B (zh) 生长抑素类似物与11β‑羟化酶抑制剂的组合
JP7444889B2 (ja) ソマトスタチン受容体陽性腫瘍のイメージング及び治療のための方法
JP2023507626A (ja) 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
KR20220157313A (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
WO2021026454A1 (en) Method of treating cancer
CN108014108A (zh) lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
CN115969839A (zh) 金合欢素或金合欢素水溶性前药在制备防治免疫性心肌炎药物中的应用
EP4401741B1 (en) Bioactive molecules for use in treating insulin resistance and/or restoring glucose homeostasis
US20050176829A1 (en) Methods for treating hypothyroidism
JP2020143037A (ja) 糖尿病合併心不全の治療用医薬組成物
Han et al. Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease
WO2025212841A1 (en) Compositions and methods for treating diseases and disorders associated with muscle weakness
WO2024156884A1 (en) Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs)
JP2021528424A (ja) 対象における食後のグルコースレベルをコントロールする方法および使用
WO2024206218A1 (en) Compositions and methods for administering paltusotine to patients with hepatic impairment
CN118434418A (zh) 用于改善心脏功能的组合物
IL311487A (en) Biologically active molecules for the treatment of diabetes
Mason 16th International Congress of Endocrinology/96th Annual Meeting and Exposition of the Endocrine Society (ICE/ENDO), Chicago, Illinois, USA-June 21-24, 2014
JP2008239499A (ja) レプチン分泌促進剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant